IBC-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
AssigneeDana-Farber Cancer Institute, Inc.
InventorsKornelia Polyak, Dale Porter
Life of this patent
Estimating the term…
Abstract
This invention encompasses antibodies specific for IBC-1 (Invasive Breast Cancer-1), methods for diagnosis and prognosis of metastatic breast cancer and degenerative neural conditions, methods of identifying and manufacturing therapeutic compounds, and methods of treating patients with invasive and metastatic breast cancer or degenerative neural conditions.
Claims16
A purified monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to an epitope within the sequence of SEQ ID NO:6 (amino acids 43-64 of pro-IBC-1).
A purified monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to an epitope within the sequence of SEQ ID NO:12 (amino acids 45-64 of pro-IBC-1).
A purified monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to an epitope within the sequence of SEQ ID NO:7 (amino acids 53-64 of pro-IBC-1).
A purified monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to an epitope within the sequence of SEQ ID NO:13 (amino acids 86-103 of pro-IBC-1).
Dependencies are inferred from the claim text.